Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients

被引：17

作者：

Riihijarvi, Sari ^{[1
,2
]}

Koivula, Satu ^{[1
,2
]}

Nyman, Heidi ^{[1
,2
]}

Rydstrom, Karin ^{[3
]}

Jerkeman, Mats ^{[3
]}

Leppa, Sirpa ^{[1
,2
]}

机构：

[1] Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland

[2] Univ Helsinki, Biomedicum, Genome Scale Biol Res Program, FIN-00029 Helsinki, Finland

[3] Lund Univ, Dept Oncol, Lund, Sweden

来源：

MODERN PATHOLOGY | 2010年 / 23卷 / 05期

关键词：

diffuse large B-cell lymphoma; R-CHOP; protein kinase C-beta II; prognosis; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; GERMINAL CENTER; ELDERLY-PATIENTS; PKC-BETA; SURVIVAL; PREDICTS; IMMUNOCHEMOTHERAPY; CLASSIFICATION; ENZASTAURIN;

D O I：

10.1038/modpathol.2010.43

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Development of targeted agents for the treatment of diffuse large B-cell lymphoma includes clinical evaluation of enzastaurin, an agent that suppresses signaling through protein kinase C-beta and AKT pathways. To determine whether protein kinase C-beta expression has prognostic significance for diffuse large B-cell lymphoma patients treated with immunochemotherapy, we analyzed the expression of protein kinase C-beta II, BCL-2 and cell of origin immunohistochemically from pretreatment samples of 95 diffuse large B-cell lymphoma patients. All patients received rituximab with CHOP or CHOEP. According to Kaplan-Meier analyses, overall survival at 3 years was better among the patients with low than high protein kinase C-beta II protein levels (94 vs 76%, P = 0.036). The prognostic value of protein kinase C-beta II expression on survival was seen in the patients with low and high International Prognostic Index risk groups, and in all molecular entities. Gene expression data from an independent set of 233 diffuse large B-cell lymphoma patients treated with a combination of rituximab and CHOP-like chemotherapy was analyzed in comparison. Accordingly, a better 3-year overall survival was observed among the subgroup with low protein kinase C-beta II mRNA levels (84 vs 68%, P = 0.005). In multivariate analysis with cell of origin, protein kinase C-beta II mRNA expression remained as an independent predictor for overall survival. Together, the data show that protein kinase C-beta II expression has prognostic significance in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Modern Pathology (2010) 23, 686-693; doi: 10.1038/modpathol.2010.43; published online 26 February 2010

引用

页码：686 / 693

页数：8

共 29 条

[1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[2] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[3] Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma [J].

Espinosa, Inigo ;

Briones, Javier ;

Bordes, Ramon ;

Brunet, Salut ;

Martino, Rodrigo ;

Sureda, Ana ;

Prat, Jaime ;

Sierra, Jorge .

ANNALS OF HEMATOLOGY, 2006, 85 (09) :597-603

[4] Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma [J].

Fu, Kai ;

Weisenburger, Dennis D. ;

Choi, William W. L. ;

Perry, Kyle D. ;

Smith, Lynette M. ;

Shi, Xinlan ;

Hans, Christine P. ;

Greiner, Timothy C. ;

Bierman, Philip J. ;

Bociek, R. Gregory ;

Armitage, James O. ;

Chan, Wing C. ;

Vose, Julie M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4587-4594

[5] The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts [J].

Graff, JR ;

McNulty, AM ;

Hanna, KR ;

Konicek, BW ;

Lynch, RL ;

Bailey, SN ;

Banks, C ;

Capen, A ;

Goode, R ;

Lewis, JE ;

Sams, L ;

Huss, KL ;

Campbell, RM ;

Iversen, PW ;

Neubauer, BL ;

Brown, TJ ;

Musib, L ;

Geeganage, S ;

Thornton, D .

CANCER RESEARCH, 2005, 65 (16) :7462-7469

[6] Protein kinase C and other diacylglycerol effectors in cancer [J].

Griner, Erin M. ;

Kazanietz, Marcelo G. .

NATURE REVIEWS CANCER, 2007, 7 (04) :281-294

[7] Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma [J].

Habermann, Thomas M. ;

Weller, Edie A. ;

Morrison, Vicki A. ;

Gascoyne, Randy D. ;

Cassileth, Peter A. ;

Cohn, Jeffrey B. ;

Dakhil, Shaker R. ;

Woda, Bruce ;

Fisher, Richard I. ;

Peterson, Bruce A. ;

Horning, Sandra J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3121-3127

[8] Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma [J].

Hans, CP ;

Weisenburger, DD ;

Greiner, TC ;

Chan, WC ;

Aoun, P ;

Cochran, GT ;

Pan, ZG ;

Smith, LM ;

Lynch, JC ;

Bociek, RG ;

Bierman, PJ ;

Vose, JM ;

Armitage, JO .

MODERN PATHOLOGY, 2005, 18 (10) :1377-1384

[9] Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J].

Hans, CP ;

Weisenburger, DD ;

Greiner, TC ;

Gascoyne, RD ;

Delabie, J ;

Ott, G ;

Müller-Hermelink, HK ;

Campo, E ;

Braziel, RM ;

Jaffe, ES ;

Pan, ZG ;

Farinha, P ;

Smith, LM ;

Falini, B ;

Banham, AH ;

Rosenwald, A ;

Staudt, LM ;

Connors, JM ;

Armitage, JO ;

Chan, WC .

BLOOD, 2004, 103 (01) :275-282

[10] Germinal center or nongerminal center DLBCL? [J].

Held, Gerhard ;

Pfreundschuh, Michael .

NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (04) :188-190

← 1 2 3 →